|
|
SAN DIEGO (MedPage Today) -- Preoperative beta-blocker use shouldn't be considered a performance measure for coronary artery bypass graft (CABG) surgery because use of the drug does not affect surgical morbidity and mortality measures, according to a large registry study.
Read from Source
|
| |
| |
| | 108 |
| |
|
|
|
|
|
|
